Cargando…

Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells

Effective treatment modality for triple-negative breast cancer (TNBC) is currently lacking due to the absence of defined receptor targets. Recently, we have demonstrated that lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and a lipid-lowering drug, can selectively inhibit TN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Huimei, Wu, Mi, Zhang, Qiuting, Lu, Lu, Yao, Hui, Chen, Sisi, Li, Ying, Zheng, Chanjuan, He, Guangchun, Deng, Xiyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Short Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171481/ https://www.ncbi.nlm.nih.gov/pubmed/32328175 http://dx.doi.org/10.7150/jca.39265

Ejemplares similares

Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins
por: Zheng, Chanjuan, et al.
Publicado: (2021)

Hexokinase 2 Is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells
por: Xue, Lian, et al.
Publicado: (2022)

Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells
por: Wu, Di, et al.
Publicado: (2019)

Nucleolar and Coiled-Body Phosphoprotein 1 Is Associated With Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer
por: Chen, Sisi, et al.
Publicado: (2022)

Nucleolar stress: is there a reverse version?
por: Lu, Lu, et al.
Publicado: (2018)

Triple-negative breast cancer: is there a treatment on the horizon?
por: Yao, Hui, et al.
Publicado: (2016)

Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma
por: Peng, Yikun, et al.
Publicado: (2017)

Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis
por: Zhang, Qiuting, et al.
Publicado: (2021)

Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance
por: Zheng, Chanjuan, et al.
Publicado: (2023)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis
por: Yang, Tao, et al.
Publicado: (2016)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years
por: Wang, Kangtao, et al.
Publicado: (2023)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Structural basis for the biosynthesis of lovastatin
por: Wang, Jialiang, et al.
Publicado: (2021)

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer
por: Bousquet, Guilhem, et al.
Publicado: (2017)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer
por: Umekita, Yoshihisa, et al.
Publicado: (2011)

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
por: García-Teijido, Paula, et al.
Publicado: (2016)

HPV infection and triple-negative breast cancers: an Italian case-control study
por: Piana, Andrea Fausto, et al.
Publicado: (2014)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer
por: Liu, Mingshan, et al.
Publicado: (2018)

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Meyer, Braydon, et al.
Publicado: (2021)

Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Integrity and Quantity Evaluation of Plasma Cell-Free DNA in Triple Negative Breast Cancer
por: Salimi, Mahdieh, et al.
Publicado: (2019)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

Triple-negative and triple-positive breast cancer cells reciprocally control their growth and migration via the S100A4 pathway
por: Dukhanina, Elena A., et al.
Publicado: (2022)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d6dj61i4ajpkjuar41n2g0k9om